news: California Pacific Medical Center Shows New Strategy for Treating Ovarian Cancer Provides Survival Benefits with Fewer Side Effects

press release

 The open-label, phase 3 randomized study was conducted by researchers at Sutter Health’s California Pacific Medical Center (CPMC) and leading cancer centers across the U.S., and suggests new strategies for personalized treatments.

 “No previous studies assessed the weekly administration of paclitaxel with bevacizumab, to target angiogenesis,” said Dr. Chan. “Moreover, there has been little research into how taxanes may have differing effects depending on the concurrent administration of bevacizumab.”

 In the study, 692 women with newly diagnosed stage II-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer who had received no prior treatment were prospectively stratified by whether they elected to receive bevacizumab, and then randomly allocated to receive either paclitaxel every three weeks plus carboplatin, or weekly paclitaxel plus carboplatin. The primary study endpoint was PFS.